Jefferies Starts Tesaro (TSRO) at Buy

Jefferies initiates coverage on Tesaro (NASDAQ: TSRO) with a Buy rating and a price target of $40.00.

Analyst Eileen Flowers comments, "With our ~$1B peak sales est for TSRO's late-stage products rolapitant ($300M) & niraparib ($700M) based on our expert discussions, we see 50% upside potential from current levels. If rolapitant expands the market (peak sales of ~$500M), we see ~25% upside beyond our PT. Given 12 month underperformance (-32% for TSRO vs. +38% for BTK), we view TSRO's current valuation offers an attractive entry point ahead of clinical/regulatory catalysts starting in mid-2015."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $27.22 yesterday.

You May Also Be Interested In

• UBS Upgrades UDR, Inc. (UDR) to Buy
• JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
• Stride Inc. (LRN) PT Raised to $73 at BMO Capital